5-α Reductase Inhibitors Drug-Drug Interaction Table: Full Class Review for Prescribers
Complete DDI table for finasteride and dutasteride, with mechanism-based interaction data, prescribing guidance, and clinical pearls at MD/PharmD level.
5-α Reductase Inhibitors: How to Select the Right Agent Within the Class
A prescriber-level guide to finasteride vs. Dutasteride: mechanism, isoenzyme coverage, approved indications, dosing, side-effect profiles, and evidence-based selection criteria for BPH and androgenetic alopecia.
Aromatase Inhibitors Monitoring Bundle: Complete Prescriber Reference
A full clinical reference on aromatase inhibitor drug class pharmacology, prescribing, and the complete monitoring bundle, bone density, lipids, joint symptoms, estradiol levels, and safety thresholds, written at MD/PharmD level.
Aromatase Inhibitors Titration & Tapering Algorithms
A prescriber-level guide to aromatase inhibitor drug classes, dosing titration approaches, and tapering considerations for breast cancer and off-label estrogen-excess management in men, with an evidence-boundary map and a clinician-discussion checklist.
Aromatase Inhibitors: How to Select the Right Agent Within the Class
A prescriber-level guide to anastrozole, letrozole, and exemestane, covering pharmacology, clinical trial data, dosing, and agent selection criteria for breast cancer and off-label estrogen management.
Bisphosphonates Drug-Drug Interaction Table: A Complete Prescriber Reference
A clinical-level review of bisphosphonate drug-drug interactions, pharmacokinetics, dosing rules, and prescribing guidance for alendronate, zoledronic acid, risedronate, ibandronate, and pamidronate, with a full DDI table and primary-source citations.
Copper Peptides Billing & Prior-Auth Playbook
A prescriber-level guide to copper peptide drug class pharmacology, compounding regulations, billing codes, and prior-authorization strategy for GHK-Cu and related peptides.
Copper Peptides Special-Populations Summary: Prescribing and Safety Guide
A clinical-level review of copper peptide pharmacology, dosing, and safety across special populations including pregnancy, pediatrics, renal impairment, and older adults. Written for prescribers and dispensing clinicians.
Systemic Estrogens Adverse-Event Management Protocols
A prescriber-level guide to recognizing, grading, and managing adverse events from systemic estrogen therapy, covering VTE, endometrial risk, cardiovascular effects, and monitoring protocols with evidence from WHI, PEPI, and current NAMS/ACOG guidelines.
Systemic Estrogens Class Overview Monograph
A prescriber-level monograph on systemic estrogens: pharmacology, formulations, dosing, indications, contraindications, monitoring, and key trial data for menopausal HRT and beyond.
GHRH Analogs Monitoring Bundle: Complete Prescriber Reference
A board-reviewed prescriber guide to the GHRH analog drug class covering sermorelin, tesamorelin, and CJC-1295. Includes baseline labs, on-therapy monitoring intervals, dose-adjustment criteria, and safety thresholds with primary-source citations.
GHRH Analogs: Selecting the Right Agent Within the Class
A clinical guide to GHRH analog selection, sermorelin, tesamorelin, CJC-1295, and modified peptides, covering pharmacology, dosing, indications, and how to choose between agents for GH axis stimulation.
Triple Agonists (GLP-1/GIP/Glucagon) Adverse-Event Management Protocols
A prescriber-level guide to managing adverse events with triple receptor agonists (GLP-1/GIP/glucagon), including retatrutide. Covers GI toxicity, cardiovascular monitoring, hepatic considerations, and dose-titration protocols grounded in Phase 2/3 trial data.
Triple Agonists (GLP-1/GIP/Glucagon) Titration and Tapering Algorithms
A prescriber-level guide to titrating and tapering retatrutide and other GLP-1/GIP/glucagon triple agonists, including dose schedules, stopping rules, and restart protocols based on current trial data.
Adverse Events with Obesity Drugs (GLP-1s): Management Guide
GI side effects hit 30-50% of GLP-1 users and cause most early stops. See dose escalation, stopping rules, and pancreatitis risk factors to keep patients on therapy.
GLP-1 Receptor Agonists: How to Select the Right Agent Within the Class
A clinical guide to selecting among GLP-1 receptor agonists, semaglutide, liraglutide, dulaglutide, tirzepatide, exenatide, based on weight, CV risk, renal function, dosing frequency, and cost. Written for prescribers and clinical pharmacists.
GH Secretagogues Adverse-Event Management Protocols
A prescriber-level guide to identifying, grading, and managing adverse events associated with GH secretagogue therapy, including ipamorelin, sermorelin, CJC-1295, and MK-677. Covers mechanism-based toxicity, monitoring schedules, and dose-adjustment algorithms.
GH Secretagogues Monitoring Bundle: A Complete Prescriber Reference
A physician-level guide to monitoring patients on GH secretagogues (ipamorelin, CJC-1295, MK-677, GHRP-2, GHRP-6). Covers baseline labs, on-therapy intervals, dose titration, safety signals, and discontinuation criteria with primary-source citations.
GH Secretagogue Side Effects: Edema, Paresthesia, Insulin Risk
Edema, paresthesia, and insulin resistance risk vary by age, sex, and comorbidity with GH secretagogues; see population-specific dosing and monitoring guidance.
Healing Peptides (BPC-157 / TB-500) Titration and Tapering Algorithms
A prescriber-level guide to BPC-157 and TB-500 dosing, titration schedules, tapering protocols, and the clinical rationale behind each step, with primary-source citations throughout.
Basal Insulin Analogs: Titration & Tapering Algorithms
A prescriber-level guide to basal insulin analog titration and tapering algorithms for T1D and T2D, including starting doses, adjustment protocols, and deprescribing strategies backed by clinical trial data.
Basaglar vs Toujeo: Which Basal Insulin Fits Your Patient
Basaglar (glargine U-100) and Toujeo (glargine U-300) differ in concentration, duration, and hypoglycemia risk. Compare profiles to pick the right agent.
Rapid-Acting Insulin Analog Adverse-Event Management Protocols
A clinician-level guide to preventing, recognizing, and managing adverse events with rapid-acting insulin analogs (lispro, aspart, glulisine, faster aspart, inhaled insulin). Includes hypoglycemia protocols, injection-site reactions, and dosing frameworks.
Rapid-Acting Insulin Analogs: Special Populations Summary
A prescriber-level review of rapid-acting insulin analogs (lispro, aspart, glulisine, ultra-rapid formulations) across pediatric, pregnant, elderly, and renal/hepatic-impaired populations, with dosing guidance and key trial data.
Rapid-Acting Insulin Analogs: Selecting the Right Agent Within the Class
A clinical guide to choosing among lispro, aspart, glulisine, faster aspart, and ultra-rapid lispro for prandial insulin coverage. Written at MD/PharmD level with head-to-head trial data, dosing nuances, and practical switching guidance.
Meglitinides Adverse-Event Management Protocols
A clinical-level review of meglitinide adverse events, prescribing protocols, hypoglycemia management, drug interactions, and patient selection for repaglinide and nateglinide.
Meglitinides Monitoring Bundle: Complete Prescribing and Safety Reference
A clinical-level review of the meglitinides drug class covering repaglinide and nateglinide dosing, blood glucose monitoring targets, hypoglycemia management, renal and hepatic dose adjustments, drug interactions, and lab surveillance for prescribers and pharmacists.
Melanocortin Receptor Agonists: Selecting the Right Agent Within the Class
A prescriber-level guide to melanocortin receptor agonists, bremelanotide, setmelanotide, afamelanotide, and investigational agents, covering mechanism, approved indications, dosing, and how to pick the right drug for each patient.
NAD Precursors Billing & Prior-Auth Playbook
A practical, MD/PharmD-level guide to billing codes, prior-authorization strategies, and prescribing essentials for NAD precursor therapies including NMN, NR, and IV NAD+.
PCSK9 Inhibitors: Selecting the Right Agent Within the Class
A prescriber-level guide to choosing between evolocumab, alirocumab, and inclisiran for FH, post-ACS, and statin-intolerant patients. Covers mechanism, dosing, trial data, payer hurdles, and a practical selection framework.
PDE5 Inhibitors Special Populations: A Prescriber-Level Summary
A board-reviewed, prescriber-level summary of PDE5 inhibitors across special populations including renal impairment, hepatic dysfunction, cardiovascular disease, older adults, and women, with dosing tables and guideline citations.
Progestins (Micronized vs Synthetic): Adverse-Event Management Protocols
A prescriber-level guide to managing adverse events from micronized progesterone and synthetic progestins, covering class differences, dose adjustments, and evidence-based switching protocols for HRT and luteal support.
RANK-L Inhibitors Adverse-Event Management Protocols
A clinical reference for prescribers and pharmacists on managing adverse events from RANK-L inhibitors (denosumab), including hypocalcemia, ONJ, atypical fractures, and rebound risk.
RANK-L Inhibitors Billing & Prior-Auth Playbook
A clinical-grade guide to RANKL inhibitor billing, prior authorization, J-code submission, step-therapy requirements, and prescribing pearls for denosumab (Prolia/Xgeva) and emerging agents.
RANK-L Inhibitors Drug-Drug Interaction Table: Complete Prescriber Reference
A physician- and pharmacist-level reference covering the RANKL inhibitor drug class, denosumab DDI table, dosing, monitoring, and clinical guidelines with primary-source citations.
RANK-L Inhibitors: Selecting the Right Agent Within the Class
A prescriber-level review of RANK-L inhibitors (denosumab, denosumab-prlia, and biosimilars), covering mechanism, approved indications, dosing, switching strategy, and how to choose between agents for osteoporosis and bone metastases.
SERMs Adverse-Event Management Protocols: A Clinical Reference for Prescribers
A clinician-level guide to managing adverse events from selective estrogen receptor modulators (SERMs), including tamoxifen, raloxifene, clomiphene, and enclomiphene. Covers mechanism, class-specific toxicities, and evidence-based mitigation strategies.
siRNA Lipid Therapeutics Drug-Drug Interaction Table: A Clinical Reference for Prescribers
A prescriber-level DDI reference for siRNA lipid therapeutics (inclisiran, vutrisiran, patisiran). Covers mechanism, pharmacokinetics, DDI table, dosing, and monitoring guidance with primary literature citations.
Sulfonylureas Adverse-Event Management Protocols
A clinical-level guide to recognizing, preventing, and managing adverse events from sulfonylurea therapy, including hypoglycemia protocols, weight gain strategies, and special-population dosing. Written for prescribers and pharmacists.
Sulfonylureas Billing & Prior-Auth Playbook
A prescriber- and pharmacist-level guide to sulfonylurea drug class pharmacology, formulary positioning, billing codes, and prior-authorization strategy for T2D management.
Sulfonylureas Monitoring Bundle: The Complete Prescriber Reference
A board-reviewed, MD/PharmD-level guide to the sulfonylureas monitoring bundle covering baseline labs, hypoglycemia protocols, renal and hepatic dose adjustments, cardiovascular safety, and drug interactions for glipizide, glyburide, and glimepiride.
Sulfonylureas Special-Populations Summary: Prescribing Guide for Complex Patients
A clinical-level review of sulfonylurea pharmacology, dosing, and special-population considerations for prescribers and pharmacists managing T2D.
Losartan vs Amlodipine: Switching Between Them and Which One Is Right for You
A detailed clinical comparison of losartan and amlodipine for hypertension, including how to switch between them safely, trial data from LIFE and ASCOT-BPLA, and guidance on which drug fits which patient profile.
Ozempic vs Liraglutide Side-Effect Profile Head-to-Head
A detailed clinical comparison of semaglutide (Ozempic) and liraglutide side-effect profiles, using SUSTAIN-7, SCALE Obesity, and FDA labeling data to help patients and clinicians choose between these two GLP-1 receptor agonists.
Wegovy vs Zepbound Head-to-Head Efficacy: What the Clinical Data Actually Show
A rigorous comparison of semaglutide 2.4 mg (Wegovy) and tirzepatide (Zepbound) for weight loss, drawing on STEP-1, SURMOUNT-1, and the first direct head-to-head trial data available.
Zepbound vs Mounjaro: Switching Between Them
Zepbound and Mounjaro both contain tirzepatide, but they carry different FDA approvals, pricing structures, and titration targets. This guide explains what changes and what stays the same when you switch between them.
Farxiga vs Metformin Side Effects: A Head-to-Head Profile
A detailed clinical comparison of dapagliflozin (Farxiga) and metformin side-effect profiles, including cardiovascular outcomes, GI tolerability, and prescribing guidance from named trials and guidelines.
Rapamycin (Sirolimus) vs Low-Dose Naltrexone: Side-Effect Profile Head-to-Head
A clinical comparison of rapamycin (sirolimus) and low-dose naltrexone (LDN) side-effect profiles for longevity and immune-modulation use, with trial data, dosing context, and prescriber guidance.
Cialis vs Sildenafil (Generic): Head-to-Head Efficacy Compared
A comparison of tadalafil (Cialis) vs generic sildenafil across dose ranges, onset, duration, side effects, and real-world trial data to help you choose the right PDE5 inhibitor.
Cialis vs Tadalafil Generic: Head-to-Head Efficacy Compared
Cialis (brand tadalafil) and generic tadalafil contain the same molecule at identical doses. This HealthRX.com clinical review compares efficacy, onset, duration, dosing, cost, and safety across every approved indication so you can make an informed choice with your prescriber.
Testosterone Cypionate vs Testosterone Enanthate Side Effects: Head-to-Head Profile
A detailed head-to-head comparison of testosterone cypionate and testosterone enanthate side-effect profiles, dosing schedules, injection site reactions, and clinical outcomes for men on TRT.
Testosterone Cypionate vs Testosterone Enanthate: Switching Between Them
A clinical comparison of testosterone cypionate and testosterone enanthate for TRT, including pharmacokinetics, dosing, injection schedules, and a step-by-step protocol for switching between them safely.
Testosterone Enanthate vs Jatenzo Side-Effect Profile Head-to-Head
A clinical comparison of testosterone enanthate injections and Jatenzo oral testosterone undecanoate covering side-effect profiles, cardiovascular risk, hematocrit, blood pressure, and how to choose between them.
Ipamorelin vs CJC-1295: Head-to-Head Efficacy Compared
A comparison of ipamorelin acetate vs CJC-1295 (modified GRF 1-29): mechanisms, GH pulse data, IGF-1 outcomes, dosing, side effects, and when to use each peptide or combine them.
Ipamorelin vs Egrifta (Tesamorelin) Side-Effect Profile: Head-to-Head Comparison
A clinical head-to-head comparison of ipamorelin acetate and tesamorelin (Egrifta) side-effect profiles, mechanism differences, dosing, and which peptide may suit your goals, prepared by the HealthRX.com Editorial Team.
Sermorelin vs Ipamorelin: Switching Between Them
A clinical comparison of sermorelin acetate and ipamorelin acetate, covering mechanism, dosing, side effects, and how to switch between them safely.
BPC-157 vs GHK-Cu Head-to-Head Efficacy: What the Evidence Actually Shows
A direct comparison of BPC-157 pentadecapeptide and copper tripeptide GHK-Cu across wound healing, tendon repair, anti-inflammatory action, and collagen synthesis, with every claim tied to primary sources.
PT-141 (Bremelanotide) vs Epitalon: Side-Effect Profile Head-to-Head
A direct comparison of the side-effect profiles of PT-141 (bremelanotide) and epitalon tetrapeptide, covering nausea rates, cardiovascular signals, injection-site reactions, and long-term safety data from clinical trials and published research.
Thymosin Alpha-1 vs AOD-9604 Side-Effect Profile Head-to-Head
A detailed clinical comparison of thymosin alpha-1 (thymalfasin) and AOD-9604 (HGH fragment 176-191) side-effect profiles, mechanisms, dosing, and use cases, prepared by the HealthRX.com Editorial Team.
Thymosin Alpha-1 vs AOD-9604: Switching Between Them
A clinical comparison of thymosin alpha-1 (thymalfasin) and AOD-9604 (HGH fragment 176-191), covering mechanisms, evidence, and how to switch between them safely.